These findings suggest that TMCO3 serves as a useful biomarker in HCC, and targeting TMCO3 may provide a potential therapeutic strategy for HCC, especially in HCC patients with a highly activated PI3K/AKT pathway. Here, SLC9D1 is linked to hepatocellular carcinoma.